PTC Therap (PTCT)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living wit...
- Open
- 73.050
- High
- 73.560
- Low
- 70.460
- Prev. Close
- 73.670
- Volume
- 802.51K
- Turnover
- 57.15M
- Avg Price
- 71.216
- Bid/Ask Ratio
- 0.99%
- Amplitude
- 4.21%
- 52wk High
- 90.870
- Volume Ratio
- 0.70
- Turnover Ratio
- 1.09%
PTC Therap Analyst Rating
View moreForecast & Rating
Aug 13, 2026Price forecast
$99.2940.79%
Forecast & RatingBuy
14analysts
- Strong buy50.00%
- Buy28.57%
- Hold14.29%
- Sell7.14%
- Strong sell0.00%
News
- PUBT · 1 day ago, 04:20 PM
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding disposes of 2,813 common shares worth $204,863.91
- GuruFocus · Aug 17 at 01:06 PM
Wells Fargo Sees Up to 52% Upside in 2 Stocks
- Market Beat · Aug 16 at 10:01 AM
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
- benzinga_article · Aug 13 at 11:28 AM
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
- Tip Ranks · Aug 13 at 05:16 AM
PTC Therapeutics (PTCT) Receives a Buy from Wells Fargo
- PUBT · Aug 12 at 03:28 PM
Sangamo selects winning bids in Chapter 11 asset auction for USD 163.55 million cash at close
